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Abstract 
Using data on incidence and secondary attack rates, we examined the protective efficacy of high-titre Ed- 
monston-Zagreb (EZ) and Schwarz (SW-HT) measles vaccines administered at 5 months. Control children 
were assigned to placebo at age 5 months and standard Schwarz (SW-std) measles vaccine at 9-10 months of 
age. A large proportion of measles cases was verified serologically. Though high-titre vaccines seemed to be 
protective before 10 months of age, a significant reduction in disease could not be demonstrated due to low 
incidence of measles. After 10 months of age, SW-std given at 10 months gave a vaccine efficacy of 100% 
and induced better protection than SW-HT (P=0*030) and EZ-HT (P=0.128) administered at 5 months. 
In studies of secondary attack rates in the compound, vaccine efficacy was 91% (75%-97%) for EZ-HT, 85% 
(40%-96%) for SW-HT, and 100% for SW-std. Attack rates were correlated with intensity of exposure 
(P=0.0006), being much higher for children exposed in the same hut than for those living in the same com- 
pound but in a different household (relative risk=3.36 [1.32-8.57]). The attack rate was significantly lower 
among vaccinated than unvaccinated children with no detectable measles antibody (relative risk=0.41 
[0.18-0-93]). In rural areas with a high coverage in the surrounding community, a single dose at 9-10 
months may provide sufficient protection. Since high-titre vaccines have been associated with higher mor- 
tality than SW-std, further improvements in measles control before 9 months may require two-dose 
strategies with standard vaccines. 
Introduction 
There has been increasing concern about measles infec- 
tion before the normal age of vaccination (AABY & CLE- 
MEWS, 1989; AABY et al., 1990a; DABIS et al., 1988; LOEN- 
ING & COOVADIA, 1983; TAYLOR et al., 1988). Measles 
before 9 months of age is connected with a high case fatality 
ratio (CFR) and it seems also to be connected with a signifi- 
cant delayed mortality (AABY et al., 1986,1990b; GARENNE 
& AABY, 1990). Several studies have shown that high-titre 
Edmonston-Zagreb measles vaccine (EZ) is capable of in- 
ducing measles antibodies even in the presence of matemal 
antibodies (MARKOWITZ et al., 1990; TIDJAM et al., 1989; 
WHITTLE et al., 1988a, 1990). Since seroconversion is 
usually considered to be equivalent to protection, the World 
Health Organization (WHO) has recommended the use of 
E 2  from the age of 6 months in areas with a high incidence 
before 9 months of age (WHO, 1990). However, there have 
been few studies of the protective efficacy of early measles 
vaccination with high-titre vaccines ( M Y  et al., 1988). 
The present study in rural Senegal. compared high- 
titre EZ and high-titre Schwarz vaccine (SW-HT) given 
at 5 months of age with standard Schwarz measles vac- 
cine (SW-std) administered at the age of 10 months 
(WHO, 1990). EZ was initially recommended for use in 
urban areas with a high incidence before 9 months of 
age. However, a uniform vaccination policy would 
clearly be an advantage from an administrative point of 
view. We therefore wanted to examine whether these 
high-titre vaccines could contribute to improved control 
of measles also in rural areas which have a lower in- 
cidence before 9 months of age than urban areas. 
After completion of the study, long-term follow-up of 
~ study children demonstrated increased mortality for reci- 
pients of high-titre vaccines. It has therefore been recom- 
mended that high-titre measles vaccines should no longer 
be used (EPI [Expanded Programme on Immunization], 
1992). However, we thought it worthwhile to document 
the vaccine efficacy (VE) of high-titre measles vaccines 
and SW-std. 
Subjects and Methods 
The study was carried out in Niakhar, Senegal, in a 
rural area with a population of about 25 O00 which had 
been under demographic surveillance since 1983 (CAN- 
TRELLE, 1969). The area is inhabited by Sereer who live 
in large compounds. The population, the demographic 
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surveillance system (GARENNE et al., 1987), and the epi- 
demiology of measles there (GARENNE & AABY, 1990) 
have been described in detail elsewhere. The surveillance 
system was based on a weekly visit by field assistants to 
all compounds in the study area to get information on 
births, migrations, deaths, and infections (measles and 
whooping cough). 
Study of high-titre measles vaccines 
All children born of mothers resident in the study area 
between 1 February 1987 and 31 January 1989 were in- 
cluded in the study. Children were allocated at random 
to receive either EZ, SW-HT or placebo at 5 months of 
age. Parents were advised to bring their children for one 
of the monthly vaccination sessions at the nearest of the 3 
health centres in the study area in the 3rd, 5th and 10th 
months after birth. At 3 months of age, children received 
bacillus Calmette-Guérin (BCG) and diphtheria, tetanus, 
pertussis and polio (DTP-IPV), at 5 months the second 
dose of DTP-IPV, and at 10 months the third dose of 
DPT-IPV and yellow fever vaccine. At the 5 months vac- 
cination (mean age 5.1 months) children received EZ, 
SW-HT or placebo. The study was 'blind' between 5 and 
10 months of age. Children in the placebo group as well 
as children who had not previously attended for vaccina- 
tion were offered vaccination with SW-std when they 
were 10 months old (mean age 10-1 months). Children 
belonging to the study cohort who did not attend for vac- 
cination at 5 months also remained under surveillance al- 
though they had not entered the study. Children who re- 
mained vaccinated were called for vaccination at a health 
centre during 2 campaigns, and at the end of the study 
period (September-December 1990) all children were 
visited at home by a physician. Measles vaccination was 
offered to those who had still not received measles vac- 
cine; 55% (1381248) accepted. 
Blood samples were collected at 5 and 10 months of 
age from children included in the study. Recipients of 
high-titre vaccine found to be serologically negative at 10 
months of age were offered revaccination against 
measles; 5 children (1%) in the EZ and 31 (10%) in the 
SW-HT thus received a second vaccination with either 
EZ or SW-std. Revaccinated children were excluded 
from the analysis of VE from the time of revaccination. 
Blood samples were not collected from the children who 
had received SW-std. 
When blood samples from the first vaccinated children 
were analysed, it became clear that SW-HT gave lower 
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seroconversion rates than EZ (unpublished observations). 
Children in the last 8 month cohorts (born between 1 
June 1988 and 31 January 1989), were therefore allocated 
to receive only EZ or placebo at 5 months of age. Thus 
there were 3 groups during the first 16 month cohorts 
but only 2 during the last 8 month cohorts. As a conse- 
quence, there were fewer children in the SW-HT group 
than in the other 2 groups. 
Vaccines 
EZ-HT and SW, kindly provided by the Institute of 
Immunology, Zagreb, (EZ, lots 81 and 137) and Institut 
Mérieux, Lyon (SW-HT), were given in a minimum 
dose of 100 O00 plaque-forming units (pfu). SW-std had 
a titre of 6000 50% tissue culture infective doses 
(TCIDso). All measles vaccines were administered sub- 
cutaneously. Samples of the vaccines used in the field 
were routinely controlled at the Medical Research Coun- 
cil (MRC) Laboratories in Fajara, The Gambia. 
Measles surveillance and clinical examination 
As soon as a field assistant was informed of a case of 
suspected measles in the weekly visit to all co'mpounds, 
the project physician was called to examine the children. 
At the first visit, a census was made of all children under 
15 years of age in the compound. Whether children lived 
in the same hut as the index case, in the same household 
but not the same hut, or in the same compound but not 
in the same household, was recorded (GARENNE & 
AABY, 1990). If the parents consented, a blood sample 
was taken from all cases and from exposed children with- 
out a parental history of measles infection. Convalescence 
samples were collected about 4-5 weeks after the begin- 
ning of symptoms from children who developed measles. 
All 55 cases with a clinical diagnosis were seen by a 
project physician and had a typical rash and/or typical 
desquamation. Eleven further cases were reported by 
parents, usually the mother. Previous studies in this area 
have shown maternal diagnoses of measles to be very re- 
liable (AABY, 1992). Most of these cases had occurred 




Blood samples were analysed for measles haemagglutin- 
ation inhibition (HAI) antibodies at the MRC Laboratories 
in The Gambia (WHITTLE et al., 1988b). The sensitivity of 
this test is 62.5 milli-international units (miu). Since the test 
starts with a 1:2 dilution, the minimum detectable level is 
125 miu. A four-fold increase in paired samples was con- 
sidered proof of acute measles infection. Protection in rela- 
tion to antibody level was analysed for children who had a 
blood sample collected within 10 d of the onset of symp- 
toms in the index case in the compound. 
Vaccine efficacy 
The protective efficacy against measles infection was 
examined by comparing incidence of measles in the dif- 
ferent groups and by determining protection against in- 
fection after known exposure at home to an index case of 
measles. Children were considered to be vaccinated from 
14 d after administration of vaccine at 5 or 10 months of 
age. Vaccine efficacy (VE) was defined as (1-relative 
risk of incidence [vaccinated/unvaccinated]) x 100. 
In the study of incidence, comparison was made for 2 
periods, bemeen 5 and 9 months of age and from 10 
months of age, when most of the children had received a 
high-titre or SW-std vaccine. Incidence was calculated as 
number of cases in relation to the number of person- 
years-at risk (PYR). PYR was calculated from 14 d after 
vaccination to the special survey in the autumn of 1990, 
the day of death, the day of migration, the day of measles 
infection, or the date of receiving a second dose of 
measles vaccine, whichever came first. Since study de- 
sign was different for the first 16 and the last 8 monthly 
cohorts, the analysis of incidence has been standardized 
for these 2 periods. 
The secondary artack rate (SAR) following exposure 
was assessed for different study groups taking intensity 
of exposure into consideration (GARENNE & AABY, 
1990). All exposed children who developed measles ex- 
perienced the onset of symptoms within an interval of 8- 
19 d if they belonged to the first generation of cases in- 
fected in the compound. Cases occurring in later 
generations within the compound were also counted as 
secondary cases. Cases were classified according to the 
closest exposure. Two children exposed twice with an in- 
terval of 6-12 months were counted only the first time 
they were exposed. 
In the analysis of incidence, we used only the unvacci- 
nated children in the placebo group as controls, since 
there could be an association between not attending for 
Vaccination and being exposed outside the study area. In 
the study of secondary attack rates, however, we also 
used the unvaccinated children in the group which had 
not entered the study. There is no reason to believe that 
susceptibility to measles is either higher or lower when 
exposed at home for children who did not receive the 
first vaccination than for other children in the com- 
munity. 
Statistics 
Relative risk (RR) and Greenland-Robins approximate 
95% confidence interval (CI) were calculated using the 
EpiInfo program (Version 5.01a). 
Results 
Scudy children and vaccine coverage 
During the study period 2467 children were born in 
the area. At the 5 months vaccination, 2177 children 
were eligible for inclusion in the study. Of these child- 
ren, 72.9% received a vaccine at 5 months: 624 received 
EZ, 321 SW-HT and 634 the placebo. Nine received the 
wrong vaccine and were excluded from the study. Of the 
control children still in the study at the 10 months vacci- 
nation, 78.7% (480/610) received SW-std. At 2 and 3 
years of age, coverage in the control group had increased 
to 86.8 and 90.4%, respectively. 
Table 1. Incidence of measles per 1000 person-years- 
at-risk according to age and vaccine group; children 
with a clinical diagnosis of measles only. Niakhar, 
Senegal, 1987-1900" 
.No.. of cases per 1000 PYRb 
Vaccine by time of exposure 
group' 5-9 months 210  months 
EZ 4-0 (1/25 1-4) 4-3 (4/929-7) 
SW-HT 0.0 (0/127*6) 8.8 W568.5)  
Placebod 11.7 (3/255.sj 19.1 (3/156.sj 
Placebo/SW-std' - 0.0 (0/826*5) 
Not in studyd 16.4 (41244.6) 57-1 (2W490.3) 
Not in study/SW-std' - 0.0 (0/397*6) 
"As only the first 16 of the 24 monthly birth cohorts in 
the study received SW-HT (see note c), the analyses of 
. vaccine efficacy have been adjusted according to 
.whether the child belonged to cohorts 1-16 or 17-24. 
Hence, some vaccine efficacies cited in the text are not 
directly deducible from the Table. The calculation of 
.vaccine efficacy has been standardized for the 2 age 
intervals in the Table. Four measles cases occurred 
before the children received measles vaccination; 2 cases 
occurred among 12 children excluded because they 
received the wrong vaccine or were vaccinated at an 
incorrect age, and one case was excluded because it had 
received 2 measles vaccines. 
bPYR= person-years-at-risk. 
'EZ =Edmonston-Zagreb vaccine; SW-HT= Schwarz 
high-titre vaccine; SW=std=standard Schwarz vaccine. 
dChildren not immunized against measles. 
'Children immumzed with the SW-std measles vaccine. 
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Measles cases 
Fifty-five of the study children were diagnosed with 
clinical measles between the beginning of the study in 
July 1987 and the autumn of 1990, most of them during 
an epidemic between September 1989 and May 1990. 
Four cases were infected before they had received their 5 
months vaccination. After 5 months of age, 5 children in 
the EZ group (2, 1, 1, 1 and 0.6 years old and 5 in the 
SW-HT group (2, 1, 1, 1, 1 years old) caught measles, 
whereas none of the recipients of SW-std were diagnosed 
with measles. None of these children died of acute 
measles. One vaccinated case was excluded from the ana- 
lysis because the child apparently had received 2 measles 
vaccines. The remaining 40 cases occurred among unvac- 
cinated children. Of the 55  cases, 28 had 2 blood samples 
collected in the acute and convalescence phase of the dis- 
ease, the rest had only one blood sample (20) or refused 
to give a blood sample (7). Of the 28 children with 2 
blood samples, 24 (86%) had a four-fold increase in the 
HAI titre; these included 2 of the 3 children in the EZ 
group and all 3 children in the SW-HT groups with 2 
samples. Three cases had the same log2 titre in both 
samples (3-3, 3-3, 5-5)  and one had no antibody in either 
sample. With 3 of the 4 cases without an increase in titre, 
there were other verified cases in the compound. The 
case who had no antibody has been maintained in the 
analysis since not all cases were examined by haemagglu- 
tination assay and the condition for inclusion was a clini- 
cal diagnosis. 
Vaccine efficacy based on incidence of measles 
The incidence in the different age and vaccine groups 
is shown in Table 1. The unvaccinated children who did 
not enter the study had a higher risk of contracting infec- 
tion than children in the placebo group who never re- 
ceived measles vaccine (RR=2.4, CI= 14-6.1). If child- 
ren with a parental diagnosis of measles were included, 
the difference in incidence was even greater (RR=2.7, 
Comparison of recipients of high-titre vaccines and unvac- 
cinated children. There were too few cases between 5 and 
10 months of age to determine VE confidently. Conside- 
ring both high-titre groups together compared with the 
placebo group, VE was 71% (-114% to 96%) (P<043). 
Compared with recipients of placebo who had not been 
vaccinated against measles, EZ had a protective efficacy 
of 75% (100/0-93%) (P=O.OSS) and SW-HT one of 11% 
(-886% to +92%) (P=0-720), if the periods both before 
and after 10 months of age were considered. 
Comparison of recipients of high-titre vaccines and SW-srd 
vaccinated children 
Compared from 10 months of age, SW-std had a VE of 
100% (P=0.003, Fisher’s exact test) compared with the 
unvaccinated children. SW-std given at 10 months of age 
also provided significantly better protection than SW- 
’ 
CI= 1.2-5-9). 
Table 2. Secondary attack rates after exposure in the compound 
according to age, intensity of exposure and vaccine group;-’only 
children with a clinical diagnosis. Niakhar, Senegal, 1987-1990 
Attack rate (Yo) (no. of casesino. exposed)” 
Placebo 
Age and place and 
nf exnnsure EZ SW-HT SW-std unvaccinated 
5-9 months 
Compound - 0.0 (0/1) - 0.0 (0/4) 
Household - - - 60.0 (3/5) 
House 0.0(0/4) - - 1000 (3/3) 
310  months 
Compound 0.0 (0/9) 0.0 (0/6) 0.0 (0/10) 33.3 (3/9) 
Household 18.2 (2111) 16.7 (116) 0.0 (0112) 80.0 (415) 
House 6.7 (2/30) 14.3 (117) 0.0 (0/32) 83.3 (15118) 
“EZ=Edmonston-Zagreb vaccine; SW-HT=Schwarz high-titre vaccine; 
SW-std=srandard Schwarz vaccine. 
HT administered at 5 months of age (P=0.030, Fisher’s 
exact test) and tended to be better than EZ administered 
at 5 months of age (P=O.128). The protective efficacy re- 
mained essentially unchanged when cases with a parental 
diagnosis only were included (data not shown). 
Vaccine efficacy based on the secondary attack rate . 
There was a highly significant tendency towards in- 
creasing SAR with intensity of exposure in the unvacci- 
nated group (P=0-0006; xz for linear trend=11.9) 
(Table 2). Children exposed in the same hut had a 3.36 
times higher risk (1.32-847) (P=0.002) of developing 
measles than did children living in the same compound 
but in a different household. The VE standardized for 
age and intensity of exposure was 91% (75%-97%) 
(P<O.OOOl) for recipients of EZ administered at 5 
months of age, 85% (40%-96%) (P=0-0002) for SW-HT 
administered at 5 months of age, and 100% (P<O.OOOl) 
for SW-std given at 10 months of age (Table 2 ) .  In com- 
pounds with at least one case confirmed serologically, the 
attack rate amofig unvaccinated children in the same 
household was 95% (19120). The only child who did not 
develop measles had a titre of 4000 miu 3 d after expo- 
sure, even though the child had no history of measles in- 
fection or vaccination against measles. 
After 10 months of age, when the different measles 
vaccines could be compared, recipients of SW-std tended 
to have better protection than those who had received 
SW-HT (P=0.104, Fisher’s exact test) or EZ vaccine 
(P=0.109, Fisher’s exact test). 
Antibody levels and protective efficacy 
Of the 169 study children exposed after the age of 5 
months, 111 (66%) had provided a blood sample within 
10 d of exposure (date of first symptom in the index case 
in the compound). All except one of the children who de- 
veloped measles were negative in the initial HAI test. 
One child in the EZ group, who was a secondary case in 
the household, had a titre of 500 miu 9 d after exposure 
and 10 d before the child developed the first symptoms 
of clinical measles. In the convalescence phase, the child 
had a titre >256 O00 miu. 
The attack rate was significantly lower among vacci- 
nated children with no detectable antibody (4/12) than 
among unvaccinated children with < 125 miu antibodies 
(1 8/22) (RR= 0.41, CI= 0.18-0.93), P= 0.008 , Fisher’s 
exact test). 
Discussion - - -  
One of the major objectives of this study was to assess 
the protective efficacy of high-titre measles vaccine be- 
tween 5 months and the normal age of vaccination. The 
observed measles incidence of 0.5% between 5 and 10 
months of age was clearly lower than the incidence of 
2.15% expected from previous data (GARENNE & MY, 
1990), probably due to the effect of vaccination cam- 
paigns launched by the Ministry of Health and UNICEF in 
1987 and the herd immunity provided by the higher vac- 
cination coverage (&BY et a¿., 1990a) resulting from the 
project. The reduced rate of measles at 5-10 months of 
age among recipients of high-titre measles vaccine 
(2.6/1000 PYR), as compared with those immunized only 
after 10 months of age (11.711000 PYR) also contributed 
to this effect, though statistically signifcant protection 
could not be shown. Thus the study had no power (15%) 
to demonstrate the expected VE (85%) of high-titre vac- 
cines between 5 and 10 months of age. However, both 
high-titre measles vaccines provided a reasonable VE in 
the secondary attack rate studies. Thus there is reason to 
think that these vaccines provide clinical protection be- 
fore the normal age of vaccination, as was found in Gui- 
nea-Bissau (AABY et al., 1988). 
The evaluation of high-titre vaccines, in particular of 
SW-HT, may well have been too favourable because sev- 
eral of the children with unmeasurable antibodies were 
revaccinated and in the exposure study children without 
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antibodies were clearly more. likely to contract measles. 
Furthermore, in :the. incidence calculation after 10 
months of age the recipients of high-titre vaccines were 
compared with children who had not been vaccinated 
with SW-std and these children may have had a higher 
risk of contacting,measles. Since EZ provided a better 
antibody response than SW-HT (our unpublished obser- 
vations), the EZ..is 'more likely to improve control of 
measles infection than high-titre Schwarz vaccine. 
No other community study from Africa has provided 
serological confirmation of a large number of cases, presum- 
ably due to the difficulties in timing when the first sample is 
taken late in the acute phase. In  the present study, in which 
most of the exposed c@ldren provided a blood sample be- 
fore exposure; signrfcant increases in titre could be demon- 
strated in most paired samples. The one child vaccinated 
with EZ whose clinical 'diagnosis was not confiied sero- 
logically was an index case who infected no one and the ex- 
clusion of this case would not affect the results obtained for 
protection after exposure at home. 
The recipients of SW-std tended to be better protected 
after 10 months of age' than the recipients of high-titre 
vaccines, though the difference was not statistically signi- 
ficant in the comparison between EZ and SW-std. This 
result is contrary. to' other studies, which have indicated 
better protection after early EZ vaccination than after 
SW-std. vaccination (AABY et al., 1988) and better sero- 
conversion after early E2 vaccination than after SW-std 
vaccination at 9 months (TIDJANI et al., 1989). The fact 
that children in the control group received SW-std at 
10.1 instead of 9.months may have improved the perfor- 
mance of the standard vaccine in the present study. 
The potential benefits of early measles vaccine with 
high-titre vaccines are related both to protection before 
the normal age; of vaccination and to the possibility of 
better protection than with SW-std after 9 months of age 
(AABY et al.; 1990a). The consequence of the low in- 
cidence before 1'0 months ,of age and of the better protec- 
tion in the SW-std group was that high-titre vaccines 
prevented .few. case? compared with the placebolSW-std 
group in spite of the lower. measles immunization cover- 
age in this group:, I'n the present study, the interval be- 
tween giving the high-titre vaccine and the standard vac- 
cine was 5 months,.yhereas it would be only 3 months in 
the normal situation when a'change is made from vacci- 
nation at 9 months'to. 6 months of age (WHO, 1990). In 
such situations; the benefits.of high-titre vaccine may be 
less. In areas with alow jncidence.of measles, and as long 
as a single dose strategy .is & h a i n e d ,  good coverage 
with the standard vaccine..at,.lO months may be as effec- 
tive for measles controlas the introduction of early vacci- 
nation with high-titremeasles vaccine if SW-std has a 
better VE after 9 months of: age, Thus the crucial issue 
for measles vaccine,.strategy. ïs. the relative VE after 9 
months of age for SW-std anci high-titre vaccines. 
Since high-titre vaccines have been protective before 9 
months of age (AABY et al.,:1990a) and SW-std was bet- 
ter than high+tre vxcines after 10 months of age in the 
present study,, two-dose strategies need to be considered. 
However, such strategies ' presuppose that the second 
dose can stimulate protective. immunity equivalent to 
that obtained by vac first time with SW- 
std at 9 months. 
In this rural areath efore 10 months of age 
was low. Hence, the ts for introduction of 
high-titre measles va reas also may be the 
simplification. oFvaccine policy. and the possibility of ob- 
taining better' coverage ..at. 6 'months of age than at 9 
months. .However, since ggh-  titre vaccines have been 
found to be associated.with higher'mortality than SW-std 
vaccine in Guinea-Bissau. (AABP et 'al., in press; EPI, 
1991) and Senegal (AABY,et a2.,"1991; GARENNE et al., 
1991) it has been recompended that high-titre measles 
vaccines no longer be;used."(EPI, 1992). It may require 
mo-dose strategies.witli standard vaccines to improve the 
control of measles,before 9 months of age. 
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Annual International Course on Identification of Arthropods and other Insects of Medical and 
Veterinary Importance 
18 Apri-I3 May  1994: London, UK 
Further information can be obtained from: Dr M. J.  R. Hall, Medical and Veterinary Division, Department 
of Entomology, The Natural History Museum, Cromwell Road, London, SW7 5BD, UK; phone 
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International Conference-Pretoria, South Afn'ca 
13-17 March 1994 
A scientific conference and workshops on the short-term future of tuberculosis in the developing world, with 
particular emphasis on Africa. 
Further details from The Secretariat, Tuberculosis-Towards 2000, MRC National Tuberculosis 
Programme, Private Bag X385, Pretoria 0001, South Africa; phone +27 12 324 1680, fax +27 12 325 5970. 
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Académie Royale de Médecine de Belgique. 
The prize is worth 500 O00 Belgian francs (about 12 500 ECU), and is intended to promote clinical, 
experimental or epidemiological research in tropical human and veterinary pathology. 
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